ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for treatment of inflammatory and renal diseases, announces
that acclaimed inflammasome researchers from the University of
Miami Miller School of Medicine and inventors of Inflammasome ASC
Inhibitor IC 100, have published a scientific paper in the
peer-reviewed journal, Frontiers in Molecular Neuroscience,
highlighting how inflammasome-mediated inflammation in Alzheimer’s
disease can trigger inflammation in the heart.
The paper titled, “Extracellular vesicles mediate inflammasome
signaling in the brain and heart of Alzheimer’s disease mice,”
summarizes research evaluating serum and tissue cultures from an AD
mouse model, and experiments of adoptive transfer of EV from AD
patients into cardiovascular cells. Following is a summary of key
findings:
- NLRP1, pyrin, caspase-1, and ASC
were significantly elevated in the cortex of AD mice.
- In AD mice, there was a heightened
level of inflammatory proteins circulating in the body via EVs
containing an inflammasome protein cargo.
- Inflammasome activation was
demonstrated in the heart of AD mice, associated with an increase
in ASC oligomerization into specks.
- In adoptive transfer experiments,
EVs released from AD patients induced significant inflammation in
cardiovascular cells when compared to EVs from healthy
individuals.
“Our data provide evidence that there is a neural-cardiac axis
mediated by EVs in AD. Therefore, inflammasomes may provide a novel
therapeutic target for the treatment of cardiac comorbidities in AD
and beyond,” said Juan Pablo de Rivero Vaccari, Associated
Professor of Neurological Surgery and The Miami Project to Cure
Paralysis at the University of Miami.
“This research reinforces the importance of attenuating
activation of multiple types of inflammasomes that govern the
inflammatory response in AD and mediating systemic inflammatory
signals in EVs to control the spread of damaging inflammation to
cardiovascular and other cells,” commented Stephen C. Glover,
ZyVersa’s Co-founder, Chairman, CEO, and President. “ZyVersa’s
Inflammasome ASC inhibitor IC 100 is designed to inhibit formation
of multiple types of inflammasomes to attenuate initiation of the
inflammatory cascade and to inhibit their associated ASC specks to
reduce spread and perpetuation of damaging inflammation.”
To review a white paper summarizing the mechanism of action and
preclinical data for IC 100, Click Here.
About Inflammasome ASC Inhibitor IC 100
IC 100 is a novel humanized IgG4 monoclonal antibody that
inhibits the inflammasome adaptor protein ASC. IC 100 was designed
to attenuate both initiation and perpetuation of the inflammatory
response. It does so by binding to a specific region of the ASC
component of multiple types of inflammasomes, including NLRP1,
NLRP2, NLRP3, NLRC4, AIM2, and Pyrin. Intracellularly, IC 100 binds
to ASC monomers, inhibiting inflammasome formation, thereby
blocking activation of IL-1β early in the inflammatory cascade. IC
100 also binds to ASC in ASC Specks, both intracellularly and
extracellularly, further blocking activation of IL-1β and the
perpetuation of the inflammatory response that is pathogenic in
inflammatory diseases. Because active cytokines amplify adaptive
immunity through various mechanisms, IC 100, by attenuating
cytokine activation, also attenuates the adaptive immune
response.
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty
biopharmaceutical company leveraging advanced, proprietary
technologies to develop first-in-class drugs for patients with
renal and inflammatory diseases who have significant unmet medical
needs. The Company is currently advancing a therapeutic development
pipeline with multiple programs built around its two proprietary
technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment
of kidney diseases, and Inflammasome ASC Inhibitor IC 100,
targeting damaging inflammation associated with numerous CNS and
other inflammatory diseases. For more information, please visit
www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
Corporate, Media, and IR Contact:Karen
CashmereChief Commercial
Officerkcashmere@zyversa.com786-251-9641
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From May 2024 to Jun 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Jun 2023 to Jun 2024